


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula (I):



wherein

Ar is

(1) phenyl,

(2) naphthyl,

(3) a 5- to 10-membered monocyclic or bicyclic heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting of oxygen, sulfur, or nitrogen, or


(4) -R<sup>9</sup>-phenyl;

wherein the phenyl, naphthyl, or heterocyclic ring is optionally substituted with halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, hydroxyl, C<sub>1-6</sub> alkoxy, OCF<sub>3</sub>, COCF<sub>3</sub>, CN, NO<sub>2</sub>, phenyloxy, phenyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>2-6</sub> alkenyl, -NR<sup>7</sup>R<sup>8</sup>, C<sub>1-6</sub> alkylcarboxyl, formyl, -C<sub>1-6</sub> alkyl-NH-CO-phenyl, -C<sub>1-6</sub> alkyl-CO-NH-phenyl, -NH-CO-C<sub>1-6</sub> alkyl, -CO-NR<sup>7</sup>R<sup>8</sup>, or SR<sup>7</sup>; wherein each of R<sup>7</sup> and R<sup>8</sup> is independently H or C<sub>1-6</sub> alkyl; and R<sup>9</sup> is C<sub>1-6</sub> alkyl or C<sub>2-6</sub> alkenyl, either of which is optionally substituted with phenyl or phenyloxy;

R<sup>2</sup> is H, phenyl, I, or C<sub>1-6</sub> alkyl;


$R^3$  is H or 3-(1-azabicyclo[2.2.2]oct-2-en)yl;

$R^4$  is selected from the group consisting of:



wherein  $R^6$  is H,  $C_{1-6}$  alkyl, or benzyl; and

$R^5$  is H, hydroxy,  $C_{1-3}$  alkoxy, F,  $NO_2$ ,  $CF_3$ ,  $OCF_3$ , or is selected from the group consisting of:



or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof,

with the proviso that when  $R^2$  is alkyl,  $R^4$  is not H.

2. (Currently Amended) The compound according to claim 1, wherein  
Ar is

(1) phenyl that is unsubstituted or optionally mono- or poly-substituted with halogen,  $C_{1-6}$  alkyl,  $CF_3$ , hydroxyl,  $C_{1-6}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl, alkylsulfonyl,  $C_{1-6}$  alkenyl,  $-NH_2$ ,  $-NHR^7$ ,  $-NR^7R^8$ ,  $C_{1-6}$  alkylcarboxyl, formyl,  $-NH-CO-C_{1-6}$  alkyl,  $-CO-NR^7R^8$ , or  $SR^7$  wherein each of  $R^7$  and  $R^8$  is independently H or  $C_{1-6}$  alkyl;

(2) 1-naphthyl or 2-naphthyl that is unsubstituted or optionally mono- or poly-substituted with halogen,  $C_{1-6}$  alkyl,  $CF_3$ , hydroxyl,  $C_{1-6}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl, alkylsulfonyl,  ~~$C_{1-6}$  alkenyl~~  $C_{2-6}$  alkenyl,  $-NH_2$ ,  $-NHR^7$ ,  $-NR^7R^8$ ,  $C_{1-6}$  alkylcarboxyl, formyl,  $-NH-CO-C_{1-6}$  alkyl,  $-CO-NR^7R^8$ , or  $SR^7$  wherein each of  $R^7$  and  $R^8$  is independently H or  $C_{1-6}$  alkyl;


(3) ~~cinnamoyl~~ cinnamoyl;

(4) benzyl;

(5) 1,1-diphenylethyl;


(6) a monocyclic or bicyclic heterocyclic ring selected from the group consisting of furyl, pyrrolyl, triazolyl, diazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrimidyl, pyrazinyl, thienyl, imidazolyl, pyrazolyl, indolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, and benzoxadiazolyl, said heterocyclic ring being optionally mono- or di-substituted substituted with halogen or  $C_{1-6}$  alkyl;

$R^4$  is selected from the group consisting of:



wherein  $R^6$  is H,  $C_{1-6}$  alkyl, or benzyl; and

$R^5$  is H, hydroxy,  $C_{1-3}$  alkoxy, F,  $NO_2$ ,  $CF_3$ ,  $OCF_3$  or is selected from the group consisting of:




3. (Previously Presented) A compound according to claim 1, wherein Ar is
- (1) phenyl,
  - (2) 1-naphthyl or 2-naphthyl,
  - (3) a 5- to 10-membered monocyclic or bicyclic heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting of oxygen, sulfur, or nitrogen, or
  - (4)  $-R^9$ -phenyl;


wherein the phenyl, naphthyl, or heterocyclic ring is optionally substituted with F, Cl, Br,  $C_{1-6}$  alkyl,  $CF_3$ , hydroxyl,  $C_{1-6}$  alkoxy,  $OCF_3$ , phenyl,  $C_{2-6}$  alkenyl,  $-NR^7R^8$ ,  $-NH-CO-C_{1-6}$  alkyl, or  $SR^7$ , wherein each of  $R^7$  and  $R^8$  is independently H or  $C_{1-6}$  alkyl; and  $R^9$  is  $C_{1-2}$  alkyl;

$R^2$  is H, phenyl, I, or  $C_{1-6}$  alkyl;

$R^4$  is selected from the group consisting of:



$R^5$  is  $C_{1-3}$  alkoxy or a heterocyclic ring selected from the group consisting of:



4. (Original) A compound according to claim 1, wherein Ar is phenyl, optionally substituted with F, Cl, Br, methyl,  $CF_3$ ,  $C_{1-4}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl, methylsulfonyl, or  $-NR^7R^8$ , where each of  $R^7$  and  $R^8$  is independently H or methyl.

5. (Original) A compound according to claim 1, wherein Ar is 1-naphthyl or 2-naphthyl, each of which is optionally substituted with F, Cl, Br, methyl,  $CF_3$ ,  $C_{1-4}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl, methylsulfonyl, or  $-NR^7R^8$ , where each of  $R^7$  and  $R^8$  is independently H or methyl.

6. (Original) A compound according to claim 1, wherein Ar is a heterocyclic ring selected from the group consisting of furyl, pyrrolyl, triazolyl, diazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridinyl, pyrimidyl, pyrazinyl, thienyl, imidazolyl, pyrazolyl, indolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, and benzoxadiazolyl, each of which is optionally substituted with halogen,  $C_{1-6}$  alkyl,  $CF_3$ , hydroxyl,  $C_{1-6}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl,  $C_{1-6}$  alkylsulfonyl,  $C_{2-6}$  alkenyl,  $-NR^7R^8$ ,  $C_{1-6}$  alkylcarboxyl, formyl,  $-NH-CO-C_{1-6}$  alkyl,  $-CO-NR^7R^8$ , or  $SR^7$ ; wherein each of  $R^7$  and  $R^8$  is independently H or  $C_{1-6}$  alkyl.

7. (Original) A compound according to claim 1, wherein Ar is a heterocyclic ring selected from the group consisting of pyridinyl, thienyl, imidazolyl, pyrazolyl, benzothienyl, and benzoxadiazolyl, each of which is optionally substituted with halogen or  $C_{1-6}$  alkyl.



8. (Original) A compound according to claim 1, wherein Ar is 2-pyridyl, 3-pyridyl, or 4-pyridyl.

9. (Original) A compound according to claim 1, wherein Ar is a 5- to 7-membered aromatic, partially saturated, or completely saturated heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting of O, S, or  $\text{NR}^{10}$ , where  $\text{R}^{10}$  is H,  $\text{C}_{1-6}$  alkyl,  $-\text{CO}-\text{CF}_3$ , or absent.

10. (Original) A compound according to claim 1, wherein Ar is  $-\text{R}^9$ -phenyl, wherein  $\text{R}^9$  is  $\text{C}_{1-3}$  alkyl or  $\text{C}_{2-3}$  alkenyl, either of which is optionally substituted with phenyl or phenyloxy, each phenyl being optionally substituted with F, Cl, Br, methyl,  $\text{CF}_3$ ,  $\text{C}_{1-4}$  alkoxy,  $\text{OCF}_3$ , CN,  $\text{NO}_2$ , phenyloxy, phenyl, methylsulfonyl, or  $-\text{NR}^7\text{R}^8$ ; and each of  $\text{R}^7$  and  $\text{R}^8$  being independently H or  $\text{C}_{1-6}$  alkyl.



11. (Original) A compound according to claim 1, wherein each of  $\text{R}^2$  and  $\text{R}^3$  is H.

12. (Previously Presented) A compound according to claim 1, wherein  $\text{R}^4$  is independently a heterocyclic ring selected from the group consisting of:




wherein  $\text{R}^6$  is H,  $\text{C}_{1-3}$  alkyl, or benzyl.


13. (Previously Presented) A compound according to claim 1, wherein Ar is phenyl, optionally substituted with F, Cl, Br, methyl, CF<sub>3</sub>, C<sub>1-4</sub> alkoxy, OCF<sub>3</sub>, CN, NO<sub>2</sub>, phenyloxy, phenyl, methylsulfonyl, or -NR<sup>7</sup>R<sup>8</sup> where each of R<sup>7</sup> and R<sup>8</sup> is independently H or methyl; each of R<sup>2</sup> and R<sup>3</sup> is H; and R<sup>4</sup> is independently a heterocyclic ring selected from the group consisting of:



wherein R<sup>6</sup> is H, C<sub>1-3</sub> alkyl, or benzyl.


14. (Previously Presented) A compound according to claim 1, wherein Ar is 1-naphthyl or 2-naphthyl, each of which is optionally substituted with F, Cl, Br, methyl, CF<sub>3</sub>, C<sub>1-4</sub> alkoxy, OCF<sub>3</sub>, CN, NO<sub>2</sub>, phenyloxy, phenyl, methylsulfonyl, or -NR<sup>7</sup>R<sup>8</sup>, where each of R<sup>7</sup> and R<sup>8</sup> is independently H or methyl; each of R<sup>2</sup> and R<sup>3</sup> is H; and R<sup>4</sup> is independently a heterocyclic ring selected from the group consisting of:






wherein  $R^6$  is H,  $C_{1-3}$  alkyl, or benzyl.

15. (Previously Presented) A compound according to claim 1, wherein Ar is a heterocyclic ring selected from the group consisting of pyridinyl, thienyl, imidazolyl, pyrazolyl, benzothienyl, and benzoxadiazolyl, each being optionally substituted with halogen or  $C_{1-6}$  alkyl; each of  $R^2$  and  $R^3$  is H; and  $R^4$  is independently a heterocyclic ring selected from the group consisting of:




H or a heterocyclic ring selected from the group consisting of:




wherein  $R^6$  is H,  $C_{1-3}$  alkyl, or benzyl.

16. (Previously Presented) A compound according to claim 1, wherein Ar is 2-pyridyl, 3-pyridyl, or 4-pyridyl; each of  $R^2$  and  $R^3$  is H; and  $R^4$  is independently a heterocyclic ring selected from the group consisting of:






H or a heterocyclic ring selected from the group consisting of:




wherein  $R^6$  is H,  $C_{1-3}$  alkyl, or benzyl.

17. (Previously Presented) A compound according to claim 1, wherein Ar is  $-R^9$ -phenyl; each of  $R^2$  and  $R^3$  is H; and  $R^4$  is independently a heterocyclic ring selected from the group consisting of:



or a heterocyclic ring selected from the group consisting of:



wherein  $R^6$  is H,  $C_{1-3}$  alkyl, or benzyl;  $R^9$  is  $C_{1-3}$  alkyl or  $C_{2-3}$  alkenyl, either of which is optionally substituted with phenyl or phenyloxy; each phenyl being optionally substituted with F, Cl, Br, methyl,  $CF_3$ ,  $C_{1-4}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl, methylsulfonyl, or  $-NR^7R^8$ ; and each of  $R^7$  and  $R^8$  being independently H or  $C_{1-6}$  alkyl.


18. (Previously Presented) A compound selected from the group consisting of:  
4-(5-aza-indolizidinyl)-1-(2-methylbenzenesulfonyl)-1H-indole hydrochloride,  
4-(3-methyl-1-piperazinyl)-1-(2-methylbenzenesulfonyl)-1H-indole hydrochloride,  
4-(*cis*-3,5-dimethyl-1-piperazinyl)-1-(2-methylbenzenesulfonyl)-1H-indole hydrochloride,  
4-((1*S*,4*S*)-2-methyl-2,5-diazabicyclo[2.2.1]heptyl)-1-(2-methylbenzenesulfonyl)-1H-indole hydrochloride,  
4-(*cis* 3,5-dimethyl-1-piperazinyl)-1-(benzenesulfonyl)-1H-indole hydrochloride[[.]],  
and  
4-(3-methylpiperazine)-(N-(4-trifluoromethyl)phenylsulfonyl)indole dihydrochloride.
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Previously Presented) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
23. (Original) A pharmaceutical composition comprising a compound of claim 18 and a pharmaceutically acceptable carrier.
24. (Currently Amended) A method of treatment of ~~a disease mediated by the serotonin related 5-HT<sub>6</sub> receptor~~ schizophrenia or depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

25. (Currently Amended) A method of treatment of ~~a disease mediated by the serotonin related 5-HT<sub>6</sub> receptor~~ schizophrenia or depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 18.

26. Canceled.

27. Canceled.

28. (Previously Presented) A compound of formula (I):



wherein

Ar is

(1) phenyl,

(2) naphthyl,

(3) a 5- to 10-membered monocyclic or bicyclic heterocyclic ring having 1 to 4 heteroatoms selected from the group consisting of oxygen, sulfur, or nitrogen, or


(4) -R<sup>9</sup>-phenyl;

wherein the phenyl, naphthyl, or heterocyclic ring is optionally substituted with halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, hydroxyl, C<sub>1-6</sub> alkoxyl, OCF<sub>3</sub>, COCF<sub>3</sub>, CN, NO<sub>2</sub>, phenyloxy, phenyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>2-6</sub> alkenyl, -NR<sup>7</sup>R<sup>8</sup>, C<sub>1-6</sub> alkylcarboxyl, formyl, -C<sub>1-6</sub> alkyl-NH-CO-phenyl, -C<sub>1-6</sub> alkyl-CO-NH-phenyl, -NH-CO-C<sub>1-6</sub> alkyl, -CO-NR<sup>7</sup>R<sup>8</sup>, or SR<sup>7</sup>; wherein each of R<sup>7</sup> and R<sup>8</sup> is independently H or C<sub>1-6</sub> alkyl; and R<sup>9</sup> is C<sub>1-6</sub> alkyl or C<sub>2-6</sub> alkenyl, either of which is optionally substituted with phenyl or phenyloxy;

$R^2$  is H, phenyl, I, or  $C_{1-6}$  alkyl;


$R^3$  is H or 3-(1-azabicyclo[2.2.2]oct-2-en)yl;

$R^4$  is H or is selected from the group consisting of:



wherein  $R^6$  is H,  $C_{1-6}$  alkyl, or benzyl; and

$R^5$  is hydroxy,  $C_{1-3}$  alkoxy, F,  $NO_2$ ,  $CF_3$ ,  $OCF_3$ , or is selected from the group consisting of:




or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof,  
with the proviso that when  $R^2$  is alkyl,  $R^4$  is not H.


29. (Previously Presented) The compound of claim 1, wherein  $R^5$  is H.

30. (Previously Presented) The compound of claim 28, wherein R<sup>4</sup> is H.
31. (Cancelled)
32. (Previously Presented) A compound that is 3-(1-azabicyclo[2.2.2]oct-2-en-3-yl)-1-[(4-fluorophenyl)sulfonyl]-1H-indole.
33. (Previously Presented) A pharmaceutical composition comprising a compound of claim 28 or 30 and a pharmaceutically acceptable carrier.
34. (Currently Amended) A method of treatment of ~~a disease mediated by the serotonin related 5-HT<sub>6</sub> receptor~~ schizophrenia or depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 28.
35. Canceled.
36. (Currently Amended) A method of treating ~~obesity, memory disorder, schizophrenia, Parkinson's disease, or~~ depression, ~~attention deficit hyperactive disorders, or drug abuse~~ comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim ~~1 or~~ 28.
37. (Currently Amended) A method of treating ~~obesity, memory disorder, schizophrenia, Parkinson's disease, or~~ depression, ~~attention deficit hyperactive disorders, or drug abuse~~ comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 29 or 30.

38. (Previously Presented) A compound according to claim 28, wherein  $R^4$  is independently H or a heterocyclic ring selected from the group consisting of:




and  $R^5$  is independently a heterocyclic ring selected from the group consisting of:




wherein  $R^6$  is H,  $C_{1-3}$  alkyl, or benzyl.

39. (Previously Presented) A compound according to claim 28, wherein Ar is phenyl, optionally substituted with F, Cl, Br, methyl,  $CF_3$ ,  $C_{1-4}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl, methylsulfonyl, or  $-NR^7R^8$  where each of  $R^7$  and  $R^8$  is independently H or methyl; each of  $R^2$  and  $R^3$  is H; and  $R^4$  is independently H or a heterocyclic ring selected from the group consisting of:




, and  $R^5$  is independently a heterocyclic ring selected from the group consisting of:




wherein  $R^6$  is H,  $C_{1-3}$  alkyl, or benzyl.

40. (Previously Presented) A compound according to claim 28, wherein Ar is 1-naphthyl or 2-naphthyl, each of which is optionally substituted with F, Cl, Br, methyl,  $CF_3$ ,  $C_{1-4}$  alkoxy,  $OCF_3$ , CN,  $NO_2$ , phenyloxy, phenyl, methylsulfonyl, or  $-NR^7R^8$ , where each of  $R^7$  and  $R^8$  is independently H or methyl; each of  $R^2$  and  $R^3$  is H; and  $R^4$  is independently H or a heterocyclic ring selected from the group consisting of:




heterocyclic ring selected from the group consisting of:




wherein  $R^6$  is H,  $C_{1-3}$  alkyl, or benzyl.

41. (Previously Presented) A compound according to claim 1, wherein Ar is a heterocyclic ring selected from the group consisting of pyridinyl, thienyl, imidazolyl, pyrazolyl, benzothienyl, and benzoxadiazolyl, each being optionally substituted with halogen or  $C_{1-6}$  alkyl; each of  $R^2$  and  $R^3$  is H; and  $R^4$  is independently H or a heterocyclic ring selected from the group consisting of:




heterocyclic ring selected from the group consisting of:




wherein R<sup>6</sup> is H, C<sub>1-3</sub> alkyl, or benzyl.

42. (Previously Presented) A compound according to claim 28, wherein Ar is 2-pyridyl, 3-pyridyl, or 4-pyridyl; each of R<sup>2</sup> and R<sup>3</sup> is H; and R<sup>4</sup> is independently H or a heterocyclic ring selected from the group consisting of:




heterocyclic ring selected from the group consisting of:




wherein R<sup>6</sup> is H, C<sub>1-3</sub> alkyl, or benzyl.



43. (Previously Presented) A compound according to claim 1, wherein Ar is -R<sup>9</sup>-phenyl; each of R<sup>2</sup> and R<sup>3</sup> is H; and R<sup>4</sup> is independently H or a heterocyclic ring selected from the group consisting of:



heterocyclic ring selected from the group consisting of:



wherein R<sup>6</sup> is H, C<sub>1-3</sub> alkyl, or benzyl; R<sup>9</sup> is C<sub>1-3</sub> alkyl or C<sub>2-3</sub> alkenyl, either of which is optionally substituted with phenyl or phenyloxy; each phenyl being optionally substituted with F, Cl, Br, methyl, CF<sub>3</sub>, C<sub>1-4</sub> alkoxy, OCF<sub>3</sub>, CN, NO<sub>2</sub>, phenyloxy, phenyl, methylsulfonyl, or -NR<sup>7</sup>R<sup>8</sup>; and each of R<sup>7</sup> and R<sup>8</sup> being independently H or C<sub>1-6</sub> alkyl.

44. (Currently Amended) A method of treatment of ~~a disease mediated by the serotonin-related 5-HT<sub>6</sub> receptor~~ schizophrenia or depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 29.

45. (Cancelled)

46. (Previously Presented) A pharmaceutical composition comprising a compound of claim 29 and a pharmaceutically acceptable carrier.

47. (Currently Amended) The compound according to claim 28, wherein Ar is

(1) phenyl that is unsubstituted or optionally mono- or poly-substituted with halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, hydroxyl, C<sub>1-6</sub> alkoxy, OCF<sub>3</sub>, CN, NO<sub>2</sub>, phenyloxy, phenyl, alkylsulfonyl, C<sub>1-6</sub> alkenyl, -NH<sub>2</sub>, -NHR<sup>7</sup>, -NR<sup>7</sup>R<sup>8</sup>, C<sub>1-6</sub> alkylcarboxyl, formyl, -NH-CO-C<sub>1-6</sub> alkyl, -CO-NR<sup>7</sup>R<sup>8</sup>, or SR<sup>7</sup> wherein each of R<sup>7</sup> and R<sup>8</sup> is independently H or C<sub>1-6</sub> alkyl;

(2) 1-naphthyl or 2-naphthyl that is unsubstituted or optionally mono- or poly-substituted with halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, hydroxyl, C<sub>1-6</sub> alkoxy, OCF<sub>3</sub>, CN, NO<sub>2</sub>, phenyloxy, phenyl, alkylsulfonyl, ~~C<sub>1-6</sub> alkenyl~~ C<sub>2-6</sub> alkenyl, -NH<sub>2</sub>, -NHR<sup>7</sup>, -NR<sup>7</sup>R<sup>8</sup>, C<sub>1-6</sub> alkylcarboxyl, formyl, -NH-CO-C<sub>1-6</sub> alkyl, -CO-NR<sup>7</sup>R<sup>8</sup>, or SR<sup>7</sup> wherein each of R<sup>7</sup> and R<sup>8</sup> is independently H or C<sub>1-6</sub> alkyl;


(3) cinnamoyl;

(4) benzyl;

(5) 1,1-diphenylethyl;


(6) a monocyclic or bicyclic heterocyclic ring selected from the group consisting of furyl, pyrrolyl, triazolyl, diazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrimidyl, pyrazinyl, thienyl, imidazolyl, pyrazolyl, indolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, and benzoxadiazolyl, said heterocyclic ring being optionally mono- or di-substituted substituted with halogen or C<sub>1-6</sub> alkyl;

R<sup>4</sup> is H or is selected from the group consisting of:




wherein R<sup>6</sup> is H, C<sub>1-6</sub> alkyl, or benzyl; and

$R^5$  is hydroxy,  $C_{1-3}$  alkoxy, F,  $NO_2$ ,  $CF_3$ ,  $OCF_3$  or is selected from the group consisting of:



48. (Currently Amended) A compound of formula (I):



wherein

$R^1$  is  $-SO_2Ar$ ;  $-SO_2(alkyl)$ ;  $-SO_2(alkyl)$ ;

Ar is phenyl, optionally substituted with F, Cl, Br,  $C_{1-6}$  alkyl,  $CF_3$ , hydroxyl,  $C_{1-6}$  alkoxy,  $OCF_3$ ,  $NO_2$ , amino, alkylamino, dialkylamino, methylcarboxyl, aminocarbonyl, or  $SR^7$ ; wherein  $R^7$  is H or  $C_{1-6}$  alkyl; 1-naphthyl, 2-naphthyl; a bicyclic heterocyclic ring or a 5- to 7-membered partially or completely saturated heterocyclic ring each having 1 to 4 heteroatoms selected from the group consisting of oxygen, sulfur, or nitrogen; and alkyl is linear or branched  $C_{1-6}$  alkyl;


$R^2$  is H or linear or branched  $C_{1-4}$  alkyl;

$R^3$  is H, or 3-(1-azabicyclo[2.2.2]oct-2-en)yl, or 3-quinuclidinyl;

[illegible]

and pharmaceutically acceptable salts, hydrates, or stereoisomeric forms thereof.

$R^4$  is selected from the group consisting of:



R<sup>5</sup> is H or C<sub>1-3</sub> alkoxy.

50. (Previously Presented) The compound of claim 48, wherein the compound is selected from:

1-(phenylsulfonyl)-4-(1-piperazinyl)-1H-indole,  
1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-1H-indole,  
1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-(1-piperazinyl)-1H-indole,  
3-(1-azabicyclo[2.2.2]oct-2-en-3-yl)-1-(phenylsulfonyl)-1H-indole,  
5-methoxy-1-(phenylsulfonyl)-4-(1-piperazinyl)-1H-indole,  
4-(4-ethyl-1-piperazinyl)-1-(phenylsulfonyl)-1H-indole,  
1-[(4-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)-1H-indole,  
1-(phenylsulfonyl)-5-(1-piperazinyl)-1H-indole,  
4-(2,5-dimethyl-1-piperazinyl)-1-(phenylsulfonyl)-1H-indole,  
4-(2,6-dimethyl-1-piperazinyl)-1-(phenylsulfonyl)-1H-indole,  
4-(1,4-diazepan-1-yl)-1-(phenylsulfonyl)-1H-indole,  
2-[1-(phenylsulfonyl)-1H-indol-4-yl]octahydropyrrolo[1,2-a]pyrazine-1-(2-naphthylsulfonyl)-4-(1-piperazinyl)-1H-indole,  
1-(1-naphthylsulfonyl)-4-(1-piperazinyl)-1H-indole,  
1-[(4-methylphenyl)sulfonyl]-4-(1-piperazinyl)-1H-indole,  
N-(1-azabicyclo[2.2.2]oct-3-yl)-N-{1-[(4-methylphenyl)sulfonyl]-1H-indol-4-yl} amine,  
2-ethyl-4-(4-ethyl-1-piperazinyl)-1-[(phenyl)sulfonyl]-1H-indole,  
4-(2,5-dimethyl-1-piperazinyl)-2-ethyl-1-(phenylsulfonyl)-1H-indole,  
4-(2,5-dimethyl-1-piperazinyl)-1-[(4-methylphenyl)sulfonyl]-2-propyl-1H-indole,  
4-(4-ethyl-1-piperazinyl)-1-[(4-methylphenyl)sulfonyl]-2-propyl-1H-indole,  
4-(4-ethyl-1-piperazinyl)-5-fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indole,  
5-fluoro-4-(1-piperazinyl)-1-{[4-(trifluoromethyl)phenyl]sulfonyl}-1H-indole,

5-chloro-1-(phenylsulfonyl)-4-(1-piperazinyl)-1H-indole,  
1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-5-methoxy-4-(1-piperazinyl)-1H-indole,  
1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-5-(1-piperazinyl)-1H-indole,  
1-[(4-methylphenyl)sulfonyl]-4-(3-methyl-1-piperazinyl)-1H-indole,  
1-[(4-methylphenyl)sulfonyl]-4-(piperidinyl)-1H-indole, or  
2-ethyl-1-(4-methyl-phenylsulfonyl)-4-(1-piperazinyl)-1H-indole.

51. (Previously Presented) The compound of claim 50, wherein the compound is 1-(phenylsulfonyl)-4-(1-piperazinyl)-1H-indole.

52. (Previously Presented) The compound of claim 50, wherein the compound is 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-1H-indole.

53. (Previously Presented) The compound of claim 50, wherein the compound is 1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-(1-piperazinyl)-1H-indole.

54. (Currently Amended) A method of treatment of ~~a disease mediated by the serotonin-related 5-HT<sub>6</sub> receptor~~ schizophrenia or depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 48.

55. (Currently Amended) A method of treatment of ~~a disease mediated by the serotonin-related 5-HT<sub>6</sub> receptor~~ schizophrenia or depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 49.

56. (Currently Amended) A method of treatment of ~~a disease mediated by the serotonin-related 5-HT<sub>6</sub> receptor~~ schizophrenia or depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 50.

57. Canceled.

58. Canceled.

59. (Previously Presented) A pharmaceutical composition comprising a compound of claim 48 and a pharmaceutically acceptable carrier.

60. (Previously Presented) A pharmaceutical composition comprising a compound of claim 49 and a pharmaceutically acceptable carrier.

61. (Previously Presented) A pharmaceutical composition comprising a compound of claim 50 and a pharmaceutically acceptable carrier.